Literature DB >> 26201791

Insulin resistance, inflammation, and nonalcoholic fatty liver disease in non-obese adults without metabolic syndrome components.

Seonah Kim1, Jaekyung Choi2, Mina Kim1.   

Abstract

PURPOSE: The purpose of the present study was to examine the association of insulin resistance and inflammation with nonalcoholic fatty liver disease (NAFLD) in non-obese adults without metabolic syndrome components.
METHODS: This was a cross-sectional study of 759 subjects aged 50 years and older. Diagnosis of NAFLD was based on sonographic evidence of fatty liver without significant alcohol consumption and another cause of chronic liver disease. Subjects without metabolic syndrome components were defined as having none of the following: high blood pressure (≥130/85 mmHg), elevated fasting glucose (≥100 mg/dl), hypertriglyceridemia (≥150 mg/dl), low high-density lipoprotein-cholesterol (men <40 mg/dl; women <50 mg/dl), and abdominal obesity measured by waist circumference ≥90 cm for men and ≥80 cm for women. The subjects were divided into quartile groups according to levels of high-sensitivity C-reactive protein (hs-CRP), homeostasis model assessment of insulin resistance (HOMA-IR), and uric acid. Odds ratios (ORs) were computed for each quartile relative to the lowest quartile group.
RESULTS: After adjustment for age, sex, smoking status, regular exercise, hs-CRP, HOMA-IR, and uric acid, a significant association was found between NAFLD and higher levels of hs-CRP, HOMA-IR, and uric acid. After adjustment for age, sex, smoking status, regular exercise, hs-CRP, HOMA-IR, and uric acid, the Ors (95 % confidence interval) of NAFLD with the highest quartile of hs-CRP, HOMA-IR, and uric acid compared with the lowest quartile were 2.58 (1.03-6.50), 2.55 (1.08-6.05), and 5.15 (1.78-14.89), respectively.
CONCLUSIONS: Insulin resistance and inflammation are independently associated with NAFLD in non-obese adults without metabolic syndrome components.

Entities:  

Keywords:  High-sensitivity C-reactive protein; Homeostasis model assessment of insulin resistance; Nonalcoholic fatty liver disease; Uric acid

Year:  2012        PMID: 26201791     DOI: 10.1007/s12072-012-9412-1

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  28 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

2.  Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice.

Authors:  Inmaculada García-Ruiz; Cristina Rodríguez-Juan; Teresa Díaz-Sanjuan; Pilar del Hoyo; Francisco Colina; Teresa Muñoz-Yagüe; José A Solís-Herruzo
Journal:  Hepatology       Date:  2006-09       Impact factor: 17.425

3.  Assessing kidney function--measured and estimated glomerular filtration rate.

Authors:  Lesley A Stevens; Josef Coresh; Tom Greene; Andrew S Levey
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

Review 4.  Serum C-reactive protein as a marker for wellness assessment.

Authors:  Pai C Kao; Shu-Chu Shiesh; Ta-Jen Wu
Journal:  Ann Clin Lab Sci       Date:  2006       Impact factor: 1.256

5.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

Review 6.  Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?

Authors:  Jesse Dawson; Matthew Walters
Journal:  Br J Clin Pharmacol       Date:  2006-12       Impact factor: 4.335

7.  Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults.

Authors:  Yong-Jae Lee; Hye-Ree Lee; Jung-Hyun Lee; Youn-Ho Shin; Jae-Yong Shim
Journal:  Clin Chem Lab Med       Date:  2010-02       Impact factor: 3.694

8.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

9.  Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men.

Authors:  Seung Ha Park; Byung Ik Kim; Jung Won Yun; Jeong Wook Kim; Dong Il Park; Yong Kyun Cho; In Kyung Sung; Chang Young Park; Chong Il Sohn; Woo Kyu Jeon; Hyang Kim; Eun Jung Rhee; Won Young Lee; Sun Woo Kim
Journal:  J Gastroenterol Hepatol       Date:  2004-06       Impact factor: 4.029

10.  Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle.

Authors:  Melvin R Hayden; Suresh C Tyagi
Journal:  Nutr Metab (Lond)       Date:  2004-10-19       Impact factor: 4.169

View more
  1 in total

1.  Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.

Authors:  Lampros Chrysavgis; Eleftheria Ztriva; Adonis Protopapas; Konstantinos Tziomalos; Evangelos Cholongitas
Journal:  World J Gastroenterol       Date:  2020-11-14       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.